| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
BetterVet is a national full-service mobile veterinary practice that provides expert vet services and telemedicine to reduce pets fear and stress. Our skilled mobile veterinarians offer a wide range of services in the comfort of your home, including i...
Global company delivering innovation-led strategy, technology, and business consulting services
Optalis Health & Rehabilitation is a company that provides post-hospital rehabilitation care, skilled nursing care, and assisted living care in South Eastern Michigan and the Columbus, Ohio area.
Sadra Medical is a Los Gatos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.